Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases

(University of Colorado Anschutz Medical Campus) Pooled analysis of three phase 1 and 2 clinical trials show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).